Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 10/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.82 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.82 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.77 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | THRB | P10828 | 1/20 | 0.75 |
| ▸ | BLM | P54132 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.75 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.71 |
| ▸ | HRH1 | P35367 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 5'-Carboxy Adenosine SCHEMBL2117314 | 1.00 | AHCY (1.00) | AHCYTMEM97HIF1ASIGMAR1ADORA2B | |
| 5'-Carboxy Adenosine SCHEMBL8981282 | 1.00 | AHCY (1.00) | AHCYTMEM97HIF1ASIGMAR1ADORA2B | |
| 5'-Carboxy Adenosine SCHEMBL3815016 | 1.00 | AHCY (1.00) | AHCYTMEM97HIF1ASIGMAR1ADORA2B | |
| 5'-Carboxy Adenosine SCHEMBL2117257 | 1.00 | AHCY (1.00) | AHCYTMEM97HIF1ASIGMAR1ADORA2B | |
| 5'-Carboxy Adenosine SCHEMBL27863662 | 0.95 | AHCY (0.91) | AHCYTMEM97HIF1ASIGMAR1ADORA2B | |
| SCHEMBL10883314 | 0.90 | AHCY (0.82) | AHCYTMEM97HIF1ASIGMAR1ADORA2B | |
| SCHEMBL13889874 | 0.90 | AHCY (1.00) | AHCYTMEM97HIF1ASIGMAR1ADORA2B | |
| SCHEMBL22354804 | 0.90 | AHCY (1.00) | AHCYTMEM97HIF1ASIGMAR1ADORA2B | |
| SCHEMBL19189542 | 0.89 | AHCY (0.80) | AHCYTMEM97HIF1ASIGMAR1ADORA2B | |
| SCHEMBL19190163 | 0.89 | AHCY (0.80) | AHCYTMEM97HIF1ASIGMAR1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119278032-A | Enhancement of persistent antitumor immunity by multifactorial immunomodulation | 贝勒医学院 | 2025-01-07 | — | — | CN | claimed |
| US-12637497-B2 | AAV capsid chimeric antigen receptors and uses thereof | UNIVERSITY OF MASSACHUSETTS (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2026106945-A2 | ENGINEERED PRIME EDITING GUIDE RNAS AND METHODS OF MAKING AND USING SAME | THE BROAD INSTITUTE, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026106943-A1 | PRIME EDITING METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETINITIS PIGMENTOSA | THE BROAD INSTITUTE, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12624354-B2 | Methods and compositions for prime editing nucleotide sequences | THE BROAD INSTITUTE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12624353-B2 | Methods and compositions for prime editing nucleotide sequences | THE BROAD INSTITUTE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12606825-B2 | — | — | 2026-04-21 | — | — | US | disclosed |
| EP-4724461-A1 | ENGINEERED VIRAL LIKE PARTICLES (EVLPS) FOR THE SELECTIVE TRANSDUCTION OF TARGET CELLS | The Broad Institute, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12599678-B2 | Methods and compositions for genomic integration | CREATE MEDICINES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12570972-B2 | Methods and compositions for prime editing nucleotide sequences | THE BROAD INSTITUTE, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| CN-110051876-B | Hydrophobic tissue adhesives | 麻省理工学院 | 2022-05-31 | — | — | CN | disclosed |
| WO-2022081954-A1 | WW-DOMAIN-ACTIVATED EXTRACELLULAR VESICLES TARGETING CORONAVIRUSES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081957-A1 | WW-DOMAIN-ACTIVATED EXTRACELLULAR VESICLES TARGETING HIV | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081987-A1 | WW-DOMAIN-ACTIVATED EXTRACELLULAR VESICLES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3980074-A1 | WATER-ACTIVATED MUCOADHESIVE COMPOSITIONS AND METHODS OF DELIVERING BIOLOGICALLY ACTIVE SUBSTANCES | The Brigham & Women's Hospital, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| CN-109310695-B | Compounds and methods for treating neurological and cardiovascular conditions | 阿斯特罗赛特制药公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114269386-A | Water-activated mucoadhesive compositions and methods for delivering bioactive substances | 布里格姆及妇女医院股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2022067130-A2 | PRIME EDITING GUIDE RNAS, COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | THE BROAD INSTITUTE, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-3950018-A1 | HYDROPHOBIC TISSUE ADHESIVES | Massachusetts Institute Of Technology (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3942042-A1 | METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES | The Broad Institute, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624354-B2 | Methods and compositions for prime editing nucleotide sequences | POLM, FEN1, SSU72 | AHCY 2427/4885TMEM97 2394/4885HIF1A 3857/4885 |
| US-12606825-B2 | — | RPRD2, METTL16, RBM15 | AHCY 1370/4885TMEM97 643/4885HIF1A 4489/4885 |
| US-12599678-B2 | Methods and compositions for genomic integration | RNGTT, UPF1, LNPEP | AHCY 2935/4885TMEM97 1469/4885HIF1A 1812/4885 |
| US-12637497-B2 | AAV capsid chimeric antigen receptors and uses thereof | HAVCR2, LPL, ICOS | AHCY 973/4885TMEM97 651/4885HIF1A 2053/4885 |
| US-12624353-B2 | Methods and compositions for prime editing nucleotide sequences | RNGTT, FEN1, POLB | AHCY 1179/4885TMEM97 2716/4885HIF1A 3988/4885 |
| US-12570972-B2 | Methods and compositions for prime editing nucleotide sequences | RNGTT, FEN1, POLM | AHCY 978/4885TMEM97 3464/4885HIF1A 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.